Article and Video CATEGORIES

Cancer Journey

Search By

Playing “Whack a Mole”: Exploring the Molecular Heterogeneity of Lung Cancer
Fri, 02/13/2009 - 15:46
Dr Pennell

Mrs. M was a 46 year-old woman who, despite having never smoked, was diagnosed with metastatic adenocarcinoma of the lung. She had a nice initial response to chemotherapy, and when she eventually progressed, she was treated with Iressa (an EGFR inhibitor similar to Tarceva which is no longer available in the US). To both her and her doctor’s delight, she had near resolution of her lung mass and most of her liver lesions after 2 months on Iressa. Unfortunately, after remaining stable for 10 months, her restaging CT scan showed one lesion in the liver was growing. Despite holding the course for another 2 months, it became evident that Mrs. M was progressing in the liver, even though her lung mass remained as stable as ever it had over the preceding year.

If you’ve ever wondered why a patient with lung cancer can have a beautiful response in one area while growing in another, or why new metastases can develop while everywhere else the disease remains stable, you aren’t alone. The truth is that cancer heterogeneity (different cancer cells or tumors in one patient behaving differently from one another) has been observed for a long time. Studies of induction chemotherapy in lung cancer (chemotherapy given in early stage disease prior to surgery) performed in the 1990’s routinely reported response rates in excess of 60%, while we know that the same chemotherapy in metastatic disease has a response rate of only 25-30%. Clearly there is something fundamentally different in the metastatic cancer than in the early stage cancers. So what gives? This concept gets to the center of the question of why cancer can initially respond to chemotherapy but eventually becomes resistant.

We know that the normal genetic machinery of lung bronchial cells can be altered by exposure to carcinogens (like tobacco smoke) and, with some contribution from underlying inherited predisposition, can give rise to lung cancer. These cancer cells frequently lose the ability to repair DNA damage, so mutations accumulate as they divide. There is an extensive body of research into the mechanisms of how tumors develop the ability to spread (metastasize) throughout the body. What is also becoming clear is that during the development of the billions of cancer cells in a patient (1 billion cells = a 1 cm tumor) the cells can develop widely different genetic makeup and behaviors, making treatment a real problem.

To illustrate this point I’ll use a study from last year by Jeff Engelman (abstract here), a lung cancer scientist at MGH in Boston. He took tumor samples from patients with lung cancer, all of which had mutations in the epidermal growth factor receptor (EGFR) that predisposed them to responding to Iressa. Eventually they progressed, and he was able to analyze changes in the EGFR gene from when they started (and responded) to when they progressed. What he found was that about half of them had developed a new mutation (called T790M) that made them resistant to Iressa. In about 20% of the resistant tumors, though, there was a totally different mechanism of resistance. The tumor cells had developed the ability to make more of a protein called MET, which could work with the EGFR to overcome Iressa. The most interesting thing from this paper was an observation in one patient (red box below) where progression was seen in both the lung and a mediastinal lymph node. He found that the primary tumor had developed the T790M, while the node did not have T790M but instead had MET amplification, leading to (at least) 2 different mechanisms of resistance in one patient.

Engelman table (Click to enlarge)

This has important ramifications for the future treatment of lung cancer. Even if we are eventually able to perform routine biopsies and determine a marker of benefit from a treatment (like EGFR mutations and Iressa/Tarceva), we now have to assume that some of those billions of cancer cells have already developed one or perhaps many ways around that treatment. Our current genetic assays are usually not sensitive enough to pick out a single mutation from the millions of other “normal” cancer cells, but even if we could we would not normally biopsy every metastatic lesion in a patient to verify that all of them had the same marker. We cannot even be sure that all of the progressing lesions in a patient are progressing for the same reason!

One way around this would be to get a more global picture of the cancer through blood tests of circulating cancer DNA, proteins, or even circulating tumor cells (CTCs), which might reflect all of the genetic changes present in the patient. Shyamala Maheswaran published a study in 2008 (described in prior post here) showing that CTCs could be used to detect very low levels of the T790M mutation in lung cancer patients with EGFR mutations, and that this predicted that the patients would eventually progress. As new mechanisms become know, this technology could be used to monitor patients for emerging resistance and allow us to adapt new drugs to overcome it. Another possible way around this is simply to begin treatment with a combination of drugs that overcome potential mechanisms of resistance (see below).

EGFR acquired resistance

(Rx is a medical abbreviation for "treat")

Although today it seems like every time we whack the mole/cancer that we see on the head with our hammer/treatment, another pops up right next to it, we are clearly gaining an understanding of why we have been failing up to this point. The era of simply using a single “best” treatment for first, second, or nth-line treatment is nearing its end, hopefully to be replaced by more rational treatments that take into account individual tumor vulnerabilities. At the risk of carrying my analogy too far, I hope in my lifetime we are able to anticipate where that mole will pop up and be waiting there, hammer in hand.

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Hi Kimberly, Welcome to Grace.  I'm sorry you are here and glad you've found us. 


It sounds like a biopsy would be the next step.  I can't speak to what...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29